Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Novel Apparatus Mimics the Human Digestive System for Oral Drug Studies

By BiotechDaily International staff writers
Posted on 15 Apr 2014
Image: Diagram of the apparatus for testing drug solubility (Photo courtesy of the University of Huddersfield).
Image: Diagram of the apparatus for testing drug solubility (Photo courtesy of the University of Huddersfield).
A team of British drug developers has created an instrument that mimics the human digestive system, which will allow them to accurately determine how orally-administered medications are dissolved and then absorbed.

Investigators at the University of Huddersfield (United Kingdom) sought a way to study the behavior of oral drugs in the digestive tract that would avoid the differences between the digestive systems of humans and laboratory animals.

To this end, they developed an apparatus for testing drug solubility that included a chamber for holding a solvent medium —often a bicarbonate based buffer system—as well as a pH probe connected to tanks of carbon dioxide and helium.

The heart of the apparatus was the control unit that monitored changes in pH of the solvent medium and, as appropriate, fed pH increasing and/or pH reducing gas from the tanks into the chamber. The control unit was able to maintain a uniform pH during testing or could be set to provide a dynamically adjustable pH range, for example to three or more different pH levels in order to test the performance of a drug carrier at different levels of acidity or alkalinity.

“By minimizing human trials we would reduce the cost of development, which is then charged to patients when the drug comes to the market—if the development costs are lower, then we can make new drugs more affordable,” said Dr. Hamid Merchant, senior lecturer of pharmaceutics at the University of Huddersfield.

Related Links:

University of Huddersfield



Channels

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.